CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it was part of a research team awarded a new $3.8 million grant from The Michael J. Fox Foundation (MJFF) to further develop an RNAi therapeutic for the treatment of Parkinson’s disease. The four-year grant, which is part of the Foundation’s LEAPS (Linked Efforts to Accelerate Parkinson’s Solutions) initiative, was awarded to Alnylam, Mayo Clinic of Jacksonville, Florida, and the Parkinson’s Institute and Clinical Center of Sunnyvale, California. MJFF fosters collaboration between industry and academia through its LEAPS program as one strategy to accelerate progress toward the development of new and improved interventions for Parkinson’s disease.
